SCHEMBL4244514

SCHEMBL4244514

NC(c1ccccc1-c1ccccc1C(=O)NCCc1ccccn1)S(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.55
CA2 P00918 2/20 0.47
CA4 P22748 1/20 0.47
KCNA5 P22460 5/20 0.47
KCNA3 P22001 2/20 0.46
KCNK3 O14649 1/20 0.46
NAMPT P43490 1/20 0.46
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
POLB P06746 2/20 0.43
TSHR P16473 1/20 0.43
LMNA P02545 2/20 0.42
PKM P14618 1/20 0.42
SLC12A2 P55011 1/20 0.42
SLC12A5 Q9H2X9 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 1/20 0.42
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4238995 0.90 HTT (0.47) HTTCA2CA4KCNA5KCNA3
SCHEMBL2209930 0.79 HTT (0.59) HTTCA2CA4KCNA5KCNA3
SCHEMBL4245385 0.76 RAB9A (0.46) CA2KCNA5SMN1; SMN2POLBLMNA
SCHEMBL4236071 0.75 MMP2 (0.40) GAALMNA
SCHEMBL4236018 0.75 ALDH1A1 (0.50) CA2KCNA5POLBLMNANPC1
SCHEMBL4248643 0.74 CA1 (0.46) CA2KCNA5LMNANPC1RAB9A
SCHEMBL5444524 0.74 KCNA5 (0.66) HTTKCNA5KCNA3KCNK3SMN1; SMN2
SCHEMBL2211818 0.73 KCNA5 (0.49) HTTKCNA5KCNA3KCNK3SMN1; SMN2
SCHEMBL20333474 0.72 NAMPT (0.50) HTTKCNA5KCNA3KCNK3NAMPT
SCHEMBL2210945 0.72 KCNA5 (0.64) HTTKCNA5KCNA3KCNK3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514582-B2 2′-substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-04-07 US disclosed
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2004-05-27 US disclosed
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2003-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171351-A1 2'-substituted 1,1'-biphenyl-2-carboxamides, process for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, KCNH1 HTT 3641/4885CA2 1130/4885CA4 2665/4885
US-20040102513-A1 2'-Substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them MLLT3, RYR2, CACNA1E HTT 3617/4885CA2 1135/4885CA4 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.